AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

1.900

+0.22013.10%

Volume:3.54M

Turnover:6.54M

Market Cap:610.57M

PE:-11.73

High:1.960

Open:1.700

Low:1.675

Close:1.680

Loading ...

Overview Company News Filings

BRIEF-Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With Nusano

Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With Nusano

THOMSON REUTERS

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Here are the top 10 ASX 200 shares today

Clarity Pharmaceuticals Signs Copper Supply Deal With US-Based Physics Firm; Shares Rise 12%

MT Newswires Live

BUZZ-Australia's Clarity Pharma gains on tax break to develop cancer platform

Clarity Pharmaceuticals Secures AU$11.1 Million Tax Incentive Refund; Shares Up 12%

MT Newswires Live

BRIEF-Clarity Pharmaceuticals Signs Commercial-Scale Copper-64 Supply Agreement

Clarity Pharmaceuticals Ltd - Clarity Signs Commercial-Scale Copper-64 Supply Agreement

THOMSON REUTERS

3 ASX Growth Companies With Up To 23% Insider Ownership

Simply Wall St.

BRIEF-Secure Trial Update First Patient Treated In The Phase Ii Cohort Expansion

Secure Trial Update: First Patient Treated in the Phase Ii Cohort Expansion

THOMSON REUTERS

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

Here are the top 10 ASX 200 shares today

Here are the top 10 ASX 200 shares today

Why Clarity, New Hope, Orthocell, and West African shares are charging higher today

Secure Trial Update: 92% of Pre-Chemo Participants Experience Greater Than 35% Drop in Psa Levels Across All Cohorts. Cohort Expansion Phase Commences.

THOMSON REUTERS

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials

Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CU6.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":1.9,"timestamp":1744870320000,"preClose":1.68,"halted":0,"volume":3540508,"delay":0,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":225167378,"shares":321351612,"eps":-0.161928,"marketStatus":"Not Yet Opened","change":0.22,"latestTime":"04-17 16:12:00 AEST","open":1.7,"high":1.96,"low":1.675,"amount":6540576,"amplitude":0.169643,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.161928,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.68,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":1.3000482564866602,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":225167378,"roa":"-36.11%","roe":"-53.99%","lyrEps":-0.154944,"volumeRatio":1.3000482564866602,"shares":321351612,"dividePrice":0,"high":1.96,"amplitude":0.169643,"preClose":1.68,"low":1.675,"week52Low":1.43,"pbRate":"4.79","psRate":"56.66","week52High":8.975,"institutionHeld":0,"latestPrice":1.9,"eps":-0.161928,"divideRate":0,"volume":3540508,"delay":0,"ttmEps":-0.161928,"open":1.7,"prevYearClose":4.17,"prevWeekClose":1.9,"prevMonthClose":2.11,"prevQuarterClose":2.11,"fiveDayClose":1.655,"twentyDayClose":2.83,"sixtyDayClose":3.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528101997","title":"BRIEF-Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With Nusano","url":"https://stock-news.laohu8.com/highlight/detail?id=2528101997","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528101997?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:20","pubTimestamp":1744896034,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With NusanoApril 17 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA8WCKN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2528717859","title":"Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With Nusano","url":"https://stock-news.laohu8.com/highlight/detail?id=2528717859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528717859?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:01","pubTimestamp":1744894861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA8WCKN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2528748056","title":"Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano","url":"https://stock-news.laohu8.com/highlight/detail?id=2528748056","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528748056?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:01","pubTimestamp":1744894860,"startTime":"0","endTime":"0","summary":"Clarity has signed a commercial-scale agreement withNusano, Inc.  for supply of copper-64  isotope.The 190,000 square footNusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci  of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, far in excess of commercial scale demands across multiple large indications.Clarity's Executive Chairperson, Dr Alan Taylor, commented, \"The signing of this Supply Agreement with Nusano will complement Clarity's existing network of US-based copper-64 suppliers, providing capacity to ensure abundant and seamless supply of the isotope. As Clarity is generating exceptional data in a number of late-stage clinical trials, we now also have a cost-effective, large-scale supply strategy locked in for the commercial roll-out of our Targeted Copper Theranostics  in the largest healthcare market in the world, the US. This Agreement is an important part","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-signs-high-volume-commercial-130100382.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-signs-high-volume-commercial-130100382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PET","CU6.AU","PET.AU","BK7047","BK4192","BK7096"],"gpt_icon":0},{"id":"2528786795","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2528786795","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528786795?lang=en_us&edition=fundamental","pubTime":"2025-04-17 15:04","pubTimestamp":1744873451,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) enjoyed a positive end to this short trading week today. After a volatile week, investors were clearly in a good mood this Thursday, sending the ASX 200 up 0.78%. That","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/17/here-are-the-top-10-asx-200-shares-today-17-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7507","BK7129","CGF.AU","LYC.AU","CU6.AU","BK7096","ALD.AU","BK7065","BK7506","BK7112","IGO.AU","BK7139","BOQ.AU","SMR.AU","ILU.AU","BK7083","KAR.AU","BK7126","BK7095","PNV.AU","BK7142","BK7508","BK7504","XJO.AU"],"gpt_icon":0},{"id":"2528629737","title":"Clarity Pharmaceuticals Signs Copper Supply Deal With US-Based Physics Firm; Shares Rise 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528629737","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528629737?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:35","pubTimestamp":1744864531,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) signed a commercial supply agreement with US-based Nusano for copper-64, a key isotope used along with the company's theranostic radiopharmaceutical SAR-bisPSMA for d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2528597737","title":"BUZZ-Australia's Clarity Pharma gains on tax break to develop cancer platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2528597737","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528597737?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:32","pubTimestamp":1744864361,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharma gains on tax break to develop cancer platform** Shares of Clarity Pharmaceuticals CU6.AX jumps 12.4% to A$1.885, highest since April 3** The radiopharmaceutical company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nL4N3QV0BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2528773278","title":"Clarity Pharmaceuticals Secures AU$11.1 Million Tax Incentive Refund; Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528773278","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528773278?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:25","pubTimestamp":1744863932,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  received an AU$11.1 million research and development tax incentive refund, inclusive of interest, as part of the Australian Federal Government's R&D Tax Incentive program, according to a Thursday Australian bourse filing.The refund will support the company's further development of its Targeted Copper Theranostic  platform of products for various cancer indications.The company has decided to prioritize the development of its two products related to diagnostic and therapeutic applications for prostate and breast cancer.To focus on the aforementioned products, the company has closed trials for two of its prostate cancer and neuroblastoma-related products.The company's shares rose 12% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","XJO.AU","XAO.AU","CU6.AU","XKO.AU"],"gpt_icon":0},{"id":"2528784570","title":"BRIEF-Clarity Pharmaceuticals Signs Commercial-Scale Copper-64 Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2528784570","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528784570?lang=en_us&edition=fundamental","pubTime":"2025-04-17 09:37","pubTimestamp":1744853835,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals Signs Commercial-Scale Copper-64 Supply AgreementApril 17 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:CLARITY SIGNS COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENTFurther company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU1LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2528200137","title":"Clarity Pharmaceuticals Ltd - Clarity Signs Commercial-Scale Copper-64 Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2528200137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528200137?lang=en_us&edition=fundamental","pubTime":"2025-04-17 07:55","pubTimestamp":1744847758,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU1LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2528272737","title":"3 ASX Growth Companies With Up To 23% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2528272737","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528272737?lang=en_us&edition=fundamental","pubTime":"2025-04-17 03:38","pubTimestamp":1744832288,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million.Operations: The company's revenue is primarily derived from its operations at the Peak Mine , Dargues Mine , and Hera Mine .Clarity Pharmaceuticals demonstrates strong growth potential, driven by its innovati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-growth-companies-23-193808763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CU6.AU","PLT.AU","BK7116","BK7506","CYC.AU","EIQ.AU","IPX.AU","IMA.AU","XAO.AU","AMI.AU","AAL.AU","BK7096","FEX.AU","TTT.AU","BK7007","BBT.AU","XJO.AU","BK7093","NWF.AU","ACR.AU","BK7508","XKO.AU","BK7016","BK7036","IPX","BK7095","BK7077","BK7078","BK7129"],"gpt_icon":0},{"id":"2527341243","title":"BRIEF-Secure Trial Update First Patient Treated In The Phase Ii Cohort Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527341243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527341243?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:37","pubTimestamp":1744724227,"startTime":"0","endTime":"0","summary":"BRIEF-Secure Trial Update First Patient Treated In The Phase Ii Cohort ExpansionApril 15 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:SECURE TRIAL UPDATE: FIRST PATIENT TREATED IN THE PHASE II COHOR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA9TRLPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2527191534","title":"Secure Trial Update: First Patient Treated in the Phase Ii Cohort Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527191534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527191534?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:02","pubTimestamp":1744722123,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA9TRLPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2527412783","title":"SECuRE trial update: First patient treated in the Phase II Cohort Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412783","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412783?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:02","pubTimestamp":1744722120,"startTime":"0","endTime":"0","summary":"The first of the planned 24 participants in the Cohort Expansion Phase  of theSECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee  after the successful completion of the Dose Escalation Phase to commence enrollment for the Cohort Expansion Phase at the 8 GBq dose level, with an increase of the number of cycles from up to 4 to up to 6.This participant will be treated with the combination of 8GBq of 67Cu-SAR-bisPSMA with enzalutamide , as per the recent protocol amendment to include a subset of participants in the Cohort Expansion Phase to receive this combination.The recently amended SECuRE trial protocol will also focus on the evaluation of metastatic castration-resistant prostate cancer  participants in the pre-chemotherapy setting. This aligns with Clarity's strategy of bringing 67Cu-SAR-bisPSMA to earlier stages of the disease and is based on its promising safety and efficacy data, esp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/secure-trial-first-patient-treated-130200983.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/secure-trial-first-patient-treated-130200983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4213","BK7001","BK7096","BK4080","PSA","BK4533","CU6.AU","BK4084","BK4231","BK4585","SRC","BK4588","BK4217","SAR","BK4135","TGA","SAR.AU","TGA.AU"],"gpt_icon":0},{"id":"2527186297","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527186297?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:01","pubTimestamp":1744614107,"startTime":"0","endTime":"0","summary":"It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By the ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/here-are-the-top-10-asx-200-shares-today-14-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SMR.AU","BK7067","XJO.AU","BK7504","PME.AU","NEU.AU","PNV.AU","BK7501","BK7129","BK7016","WHC.AU","BK7507","CU6.AU","SDR.AU","BK7083","MSB.AU","BK7096","BK7126","BK7094","BK7062","PNI.AU","BK7095","BK7508","MIN.AU"],"gpt_icon":0},{"id":"2520453608","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453608","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453608?lang=en_us&edition=fundamental","pubTime":"2025-03-20 13:57","pubTimestamp":1742450254,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) enjoyed an enthusiastic rebound today as investors brushed off the worries that dominated the markets yesterday to push decisively higher. By the time the markets clos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/20/here-are-the-top-10-asx-200-shares-today-20-march-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7062","MSB.AU","BK7054","BK7112","DYL.AU","XJO.AU","AD8.AU","BK7042","BOE.AU","CU6.AU","BK7096","TPG.AU","CGF.AU","NWL.AU","HUB.AU","BK7501","BK7503","BK7083","BK7067","BK7073","BK7508","PNI.AU"],"gpt_icon":1},{"id":"2520516496","title":"Why Clarity, New Hope, Orthocell, and West African shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520516496","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520516496?lang=en_us&edition=fundamental","pubTime":"2025-03-18 10:11","pubTimestamp":1742263881,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on form again and pushing higher on Tuesday. In afternoon trade, the benchmark index is up 0.2% to 7,870.2 points. Four ASX shares that are rising more than most tod","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/18/why-clarity-new-hope-orthocell-and-west-african-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","XJO.AU","BK7506","BK7083","BK7067","HOPE","OCC.AU","BK4211","NHC.AU","WAF.AU","BK7104","BK7096","CU6.AU"],"gpt_icon":0},{"id":"2517140149","title":"Secure Trial Update: 92% of Pre-Chemo Participants Experience Greater Than 35% Drop in Psa Levels Across All Cohorts. Cohort Expansion Phase Commences.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517140149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517140149?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:44","pubTimestamp":1741182242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nTUA4SKLS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2517261912","title":"SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517261912","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517261912?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:44","pubTimestamp":1741182240,"startTime":"0","endTime":"0","summary":"Safety Review Committee  meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase  of the SECuRE study.Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, theSRC confirmed expansion at 8 GBq dose level and recommended to increase the number of cycles from up to 4 to up to 6.Cohort 4 of the Dose Escalation Phase of theSECuRE trial, assessing multiple administrations of 67Cu-SAR-bisPSMA, is complete. Prostate-specific antigen  levels are continuing to drop in 3 participants,with reductions ≥80% observed in 3 cases so far. A complete response was achieved in a participant in cohort 4 following 2 doses of 12 GBq of 67Cu-SAR-bisPSMA to date, based on the Response Evaluation Criteria in Solid Tumors v1.1 .Across all cohorts, 68% of participants have shown reductions inPSA levels, despite the vast majority of the participants (77%) only receiving a single dose of 67Cu-SAR-bisPSMA. The majority of part","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/secure-trial-92-pre-chemo-134400223.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/secure-trial-92-pre-chemo-134400223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4080","PSA","TGA","BK7095","BK4213","SRC","RLT.AU","CU6.AU","BK7142","BK7001","ADT","BK4585","BK4231","BK4192","BK4135","ADT.AU","TGA.AU","BK4084","BK4165","BK7096","BK4588","BK7084","SAR.AU","BK4217","BK4533","SAR","DLT.AU"],"gpt_icon":0},{"id":"2517635952","title":"Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2517635952","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517635952?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:33","pubTimestamp":1741149193,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  has signed a deal with the Australian Institute for Bioengineering and Nanotechnology , located within the University of Queensland, for the supply of the copper-64  isotope used in the manufacture of diagnostic 64Cu-SAR-bisPSMA.Clarity will use the isotope to support the Phase III Clarify and Amplify registrational trials, an ongoing Co-PSMA  investigator-initiated trial and the SECuRE theranostic trial, all based in Australia.It will also benefit the advancement of Clarity’s pre-clinical schedule, including the SAR-bisFAP and SAR-trastuzumab theranostic programs.Clarity executive chair Dr Alan Taylor said the supply agreement would ultimately benefit Australian patients and their treating clinicians.“This agreement builds on years of close ties between Clarity and the Australian scientific and clinical communities and reflects our strong focus on continued partnership and synergies that can be derived from these important collaborations,” he said.The AIBN hou","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Clarity-Pharmaceuticals-ASX-CU6-Cu-64-Supply-Agreement-University-Queensland.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Clarity-Pharmaceuticals-ASX-CU6-Cu-64-Supply-Agreement-University-Queensland.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/clarity-pharmaceuticals-copper-64-isotope-supply-prostate-cancer-trials/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["XKO.AU","XAO.AU","XJO.AU","BK7096","CU6.AU"],"gpt_icon":0},{"id":"2517195715","title":"Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195715","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195715?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:25","pubTimestamp":1741141539,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having another tough session on Wednesday. In afternoon trade, the benchmark index is down a disappointing 1.2% to 8,099.7 points. Four ASX shares that have not let ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/05/why-appen-clarity-qantas-and-resolute-shares-are-pushing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK4080","BK7061","BK4231","BK7503","QAN.AU","SRC","CU6.AU","APX.AU","RSG.AU","XJO.AU","BK7104","BK7506","BK7030"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[]}}